New hope for lymphoma patients who Can't have chemo
NCT ID NCT04417166
First seen Apr 20, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study tests a combination of the drug pembrolizumab and standard radiation for people with a rare type of lymphoma (NK/T-cell) that hasn't been treated yet and is in early stages. Participants must be unable to receive full-dose chemotherapy due to age or other health factors. The goal is to see if this drug-radiation approach can control the cancer for at least two years without major side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, EXTRANODAL NK-T-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Rui-Jin Hospital
Shanghai, 200025, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
Conditions
Explore the condition pages connected to this study.